Bernstein Maintains a Hold Rating on Merck & Co. (MRK)

Merck & Co., Inc. (NYSE:MRK) is one of the best large cap value stocks to buy now. Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK) on September 25 without assigning a price target.

Merck & Co., Inc. (NYSE:MRK) reported $15.8 billion in total worldwide sales in fiscal Q2 2025, down 2% compared to fiscal Q2 2024, both nominally and excluding the impact of foreign exchange.

GAAP EPS for the quarter was $1.76, while non-GAAP EPS was $2.13. Management reported that GAAP and non-GAAP EPS include “a charge of $0.07 per share for closing of Hengrui Pharma License Agreement”.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.